Characteristics, treatment patterns, effectiveness, and discontinuation rates of rheumatoid arthritis patients treated with baricitinib or other advanced therapies in Germany (RA-BE-REAL Study)

Introduction: Baricitinib (BARI) is a Janus kinase (JAK1/2) inhibitor approved for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). RA-BE-REAL is a prospective, multinational, observational study, evaluating time until discontinuation following either BARI, biologic disease-modifying [for full text, please go to the a.m. URL]

Institutions

Publication Details

Journal
German Medical Science (German Research Foundation)
Published
2024-09-18
DOI
https://doi.org/10.3205/24dgrh155
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Characteristics, treatment patterns, effectiveness, and discontinuation rates of rheumatoid arthritis patients treated with baricitinib or other advanced therapies in Germany (RA-BE-REAL Study)

German Medical Science (German Research Foundation)
Rheumatoid Arthritis Research and Therapies
article

Characteristics, treatment patterns, effectiveness, and discontinuation rates of rheumatoid arthritis patients treated with baricitinib or other advanced therapies in Germany (RA-BE-REAL Study)

article en

Abstract

Introduction: Baricitinib (BARI) is a Janus kinase (JAK1/2) inhibitor approved for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). RA-BE-REAL is a prospective, multinational, observational study, evaluating time until discontinuation following either BARI, biologic disease-modifying [for full text, please go to the a.m. URL]

German Medical Science (German Research Foundation)
Eli Lilly (United States) (US), Experimental Factory Magdeburg (DE), Schlosspark-Klinik (DE), Orthopädische Praxis (DE), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 54%
Rheumatoid Arthritis Research and Therapies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Characteristics, treatment patterns, effectiveness, and discontinuation rates of rheumatoid arthritis patients treated with baricitinib or other advanced therapies in Germany (RA-BE-REAL Study) · German Medical Science (German Research Foundation) (2024) | TGRS Research Map | TGRS